← Human Trials & Peer-Reviewed Studies
Comparing the effects of twice-daily exenatide and insulin on renal function in patients with type 2 diabetes mellitus: secondary analysis of a randomized controlled trial
Plain-language guide to PMID 35725020 (2022): randomized controlled trial study of Exenatide in 52 patients.
Key Facts
- PMID
- 35725020
- Journal
- Journal of investigative medicine : the official publication of the American Federation for Clinical Research
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Zhang J et al. (10 authors)
- DOI
- 10.1136/jim-2021-002237
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exenatide, published as a randomized controlled trial.
Data from the RCT study was used to evaluate the effect of exenatide or insulin given for 52 weeks on estimated glomerular filtration rate (eGFR) in patients with T2DM.
Why It Was Studied
This is a secondary analysis of a randomized controlled trial (RCT) on the effects of the glucagon-like peptide-1 receptor agonists exenatide and insulin aspartate 30 injection on carotid intima-media thickness.
Here, the researchers report the renal outcomes of the intervention in patients with type 2 diabetes mellitus (T2DM).
Who Took Part
The study group was 52 patients.
How the Study Was Run
In design terms this was a randomized study.
Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The methods mention a period of 52 weeks.
What Was Measured
This is a secondary analysis of a randomized controlled trial (RCT) on the effects of the glucagon-like peptide-1 receptor agonists exenatide and insulin aspartate 30 injection on carotid intima-media thickness.
Here, the researchers report the renal outcomes of the intervention in patients with type 2 diabetes mellitus (T2DM).
Topics PubMed links to this paper include Aspartic Acid, Diabetes Mellitus, Type 2, Exenatide, Glucagon-Like Peptide-1 Receptor, Glycated Hemoglobin, Hypoglycemic Agents and Insulin.
The authors tagged it with the keywords renal insufficiency.
What This Means in Plain Language
The paper is a randomized study of Exenatide in 52 patients over 52 weeks.
The publication is from 2022 (Journal of investigative medicine : the official publication of the American Federation for Clinical Research), a journal based in England.
More context: the Exenatide compound page, all human trials.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.